All News
Gout is Undermanaged
Gout should be one of the easiest and best managed of rheumatic disorders. However, numerous deficits exist with regard to the treatment and long-term care of gout.
Read Article
Increased Cardiovascular Risk with Gout
Most patients who present with gout to rheumatology clinics are at very high risk of cardiovascular (CV) disease, Spanish researchers found.
Read Article
Statins Don't Increase Risk of Colchicine Myopathy
Neuromyopathy is a rare side effect of chronic colchicine use. Statins are more commonly implicated as a cause of drug-induced myopathy.
Given the frequent occurrence of the metabolic syndrome, simultaneous use of both colchicine and statins is common.
Read Article
The RheumNow Week in Review – 2 December 2016
Dr. Cush highlights reports from this week on RheumNow.com.
Read Article
RheumNow Week in Review – 4 November 2016
Dr. Jack Cush reviews highlights and reports from this week on RheumNow.com, including drug-induced cutaneous lupus, pediatric lupus being worse, new gout drug SEL-12, Gut microbiome and IgA plasmablasts, and the weakly-received new ACP guidelines on gout.
Read Article
Bariatric Surgery Thwarts Gout and Hyperuricemia
The rising incidence of gout has been directly linked to the obesity epidemic. The influence of obesity on gout was further tested in a cohort study of obese patients undergoing bariatric surgery as part of the Swedish Obese Subjects (SOS) study.
Read Article
ACP Gout Guidelines Reviewed and Critiqued by Rheumatologists
ACP released clinical practice guidelines for the diagnosis and management of gout. Interestingly, these are not always aligned with the 2012 ACR gout guidelines.
Read Article
October-September 2016 Top Social Media News
Following is a list of top tweets in September and October 2016; they were selected based on the number of clicks, retweets and likes by the viewership. More than 40,000 people were reached with the first one on our list.
Read Article
RheumNow Week in Review – 7 October 2016
Dr. Jack Cush reviews highlights from the journals and news this week on RheumNow.com.
Read Article
Zurampic Helps Allopurinol Non-Responders
Lesinurad (Zurampic) was approved earlier this year as adjunctive therapy to other urate-lowering therapies. It is a selective uric acid reabsorption inhibitor (URAT-1 inhibitor) designed to treat gout, and be used in combination with other xanthine oxidase inhibitors.
Read Article
RheumNow Week in Review – 26 August 2016
Dr. Jack Cush reviews news and journal reports from the past week on RheumNow.com.
Read Article
RheumNow Week in Review – 19 August 2016
Dr. Cush reviews the RheumNow.com highlights in rheumatology for the week ending 19 August 2016.
Read Article
DASH Diet: A Role in Gout?
People with hyperuricemia who followed the blood-pressure-lowering DASH diet showed significant decreases in serum urate levels, post-hoc analysis of data from an influential randomized study found.
In the Dietary Approaches to Stop Hypertension (DASH) study, participants adhering to the diet, which emphasizes the consumption of vegetables, fruits, and low-fat dairy foods as well as whole grains, poultry, fish, and nuts, had a mean decrease in serum urate levels of -0.35 mg/dL (95% CI -0.65 to -0.05), according to Stephen P. Juraschek, MD, PhD, of Johns Hopkins University, and colleagues.
EULAR Updates Gout Guidelines
A EULAR task force of 24 individuals (including 15 rheumatologists) have updated their previous 2006 guidelines for gout. The current update, which includes 11 recommendations, is based on a systematic literature review and a Delphi consensus approach to recommendations.
Read Article
RheumNow Week in Review - 29 July 2016
Dr Jack Cush reviews this week's highlights from RheumNow.com.
Read Article
RheumNow Week in Review – 1 July 2016
Dr. Jack Cush reviews highlights from the news and social media in the past week on RheumNow.com
Hyperuricemia Increases Risk of Diabetes, Death and CV Disorders in Hypertensive Patients
While hyperuricemia is linked to gout and many of the elements that make up the metabolic syndrome, it's not so clear that hyperuricemia is an independant risk factor for hypertension, diabetes, cardiovascular outcomes, etc.
Read Article
Hospitalizations Decline for Rheumatoid Arthritis, But Increase in Gout
JAMA has reported the results of an 18-year National Inpatient Sample, a database of US non-federal hospitalizations.
Read Article
RheumNow Week in Review - 3 June 2016
This week's highlights from RheumNow.com include:
Read Article
Arhalofenate, URAT-1 Inhibitor, Being Developed for Gout
Good news for gout patients includes the recent approval of Zurampic (lesinurad), a URAT-1 inhibitor, and that effective urate-lowering therapy has significant long-term cardiovascular benefits.
Read Article
